Variations of Subunit of the Mycobacterium tuberculosis F1Fo ATP Synthase and a Novel Model for Mechanism of Action of the Tuberculosis Drug TMC207 (original) (raw)

2013, Antimicrobial Agents and Chemotherapy

AI-generated Abstract

Mycobacterium tuberculosis poses a critical global health challenge, with a high burden of drug-resistant strains. TMC207, a diarylquinoline, shows promise as a new drug targeting ATP synthesis in M. tuberculosis, effectively killing both replicating and dormant bacteria. This work provides insights into the variations of the ATP synthase subunit structure and proposes a model elucidating the mechanism of action of TMC207, highlighting its potential for treating multidrug-resistant tuberculosis.

checkGet notified about relevant papers

checkSave papers to use in your research

checkJoin the discussion with peers

checkTrack your impact

Variations of Subunit of the Mycobacterium tuberculosis F1Fo ATP Synthase and a Novel Model for Mechanism of Action of the Tuberculosis Drug TMC207 (original) (raw)

Sign up for access to the world's latest research.